These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23908594)

  • 1. Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
    Nagaria TS; Williams JL; Leduc C; Squire JA; Greer PA; Sangrar W
    Neoplasia; 2013 Aug; 15(8):939-51. PubMed ID: 23908594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
    Pal HC; Diamond AC; Strickland LR; Kappes JC; Katiyar SK; Elmets CA; Athar M; Afaq F
    Oncotarget; 2016 Jan; 7(2):1227-41. PubMed ID: 26517521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
    Kacan T; Altun A; Altun GG; Kacan SB; Sarac B; Seker MM; Bahceci A; Babacan N
    Asian Pac J Cancer Prev; 2014; 15(7):3185-9. PubMed ID: 24815468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF
    Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
    Du W; Zhou JR; Wang DL; Gong K; Zhang QJ
    World J Surg Oncol; 2012 Apr; 10():60. PubMed ID: 22520038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
    Eum KH; Ahn SK; Kang H; Lee M
    Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.
    Nagaria TS; Shi C; Leduc C; Hoskin V; Sikdar S; Sangrar W; Greer PA
    Oncotarget; 2017 Oct; 8(46):80804-80819. PubMed ID: 29113345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
    Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
    Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Chuckalovcak J; Stringer DK; Koromilas AE; Boone DL; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(17):23608-32. PubMed ID: 27015562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
    Morgillo F; Martinelli E; Troiani T; Orditura M; De Vita F; Ciardiello F
    PLoS One; 2011; 6(12):e28841. PubMed ID: 22174910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
    Groenendijk FH; Mellema WW; van der Burg E; Schut E; Hauptmann M; Horlings HM; Willems SM; van den Heuvel MM; Jonkers J; Smit EF; Bernards R
    Int J Cancer; 2015 Mar; 136(6):1434-44. PubMed ID: 25080865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
    PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
    Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
    Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
    Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.